Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of DKK 84.96 billion. The enterprise value is 63.68 billion.
Market Cap | 84.96B |
Enterprise Value | 63.68B |
Important Dates
The last earnings date was Thursday, May 8, 2025.
Earnings Date | May 8, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Genmab has 61.59 million shares outstanding. The number of shares has decreased by -61.77% in one year.
Current Share Class | 61.59M |
Shares Outstanding | 61.59M |
Shares Change (YoY) | -61.77% |
Shares Change (QoQ) | +587.81% |
Owned by Insiders (%) | 1.12% |
Owned by Institutions (%) | 53.51% |
Float | 60.90M |
Valuation Ratios
The trailing PE ratio is 10.89 and the forward PE ratio is 13.75. Genmab's PEG ratio is 48.22.
PE Ratio | 10.89 |
Forward PE | 13.75 |
PS Ratio | 3.81 |
PB Ratio | 2.32 |
P/TBV Ratio | 3.87 |
P/FCF Ratio | 10.62 |
P/OCF Ratio | 10.31 |
PEG Ratio | 48.22 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.95, with an EV/FCF ratio of 7.96.
EV / Earnings | 8.10 |
EV / Sales | 2.86 |
EV / EBITDA | 7.95 |
EV / EBIT | 8.41 |
EV / FCF | 7.96 |
Financial Position
The company has a current ratio of 5.34, with a Debt / Equity ratio of 0.03.
Current Ratio | 5.34 |
Quick Ratio | 5.32 |
Debt / Equity | 0.03 |
Debt / EBITDA | 0.12 |
Debt / FCF | 0.12 |
Interest Coverage | 59.70 |
Financial Efficiency
Return on equity (ROE) is 22.80% and return on invested capital (ROIC) is 13.34%.
Return on Equity (ROE) | 22.80% |
Return on Assets (ROA) | 11.54% |
Return on Invested Capital (ROIC) | 13.34% |
Return on Capital Employed (ROCE) | 18.83% |
Revenue Per Employee | 8.45M |
Profits Per Employee | 2.98M |
Employee Count | 2,682 |
Asset Turnover | 0.54 |
Inventory Turnover | 11.54 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.44% in the last 52 weeks. The beta is 0.90, so Genmab's price volatility has been similar to the market average.
Beta (5Y) | 0.90 |
52-Week Price Change | -29.44% |
50-Day Moving Average | 1,331.65 |
200-Day Moving Average | 1,524.37 |
Relative Strength Index (RSI) | 54.87 |
Average Volume (20 Days) | 192,776 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genmab had revenue of DKK 22.30 billion and earned 7.86 billion in profits. Earnings per share was 126.72.
Revenue | 22.30B |
Gross Profit | 21.21B |
Operating Income | 7.58B |
Pretax Income | 9.13B |
Net Income | 7.86B |
EBITDA | 7.90B |
EBIT | 7.58B |
Earnings Per Share (EPS) | 126.72 |
Balance Sheet
The company has 22.27 billion in cash and 986.95 million in debt, giving a net cash position of 21.28 billion or 345.49 per share.
Cash & Cash Equivalents | 22.27B |
Total Debt | 986.95M |
Net Cash | 21.28B |
Net Cash Per Share | 345.49 |
Equity (Book Value) | 36.55B |
Book Value Per Share | 577.05 |
Working Capital | 22.64B |
Cash Flow
In the last 12 months, operating cash flow was 8.24 billion and capital expenditures -242.21 million, giving a free cash flow of 8.00 billion.
Operating Cash Flow | 8.24B |
Capital Expenditures | -242.21M |
Free Cash Flow | 8.00B |
FCF Per Share | 129.86 |
Margins
Gross margin is 95.12%, with operating and profit margins of 33.97% and 35.27%.
Gross Margin | 95.12% |
Operating Margin | 33.97% |
Pretax Margin | 40.94% |
Profit Margin | 35.27% |
EBITDA Margin | 35.43% |
EBIT Margin | 33.97% |
FCF Margin | 35.87% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 61.77% |
Shareholder Yield | n/a |
Earnings Yield | 9.26% |
FCF Yield | 9.41% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Genmab has an Altman Z-Score of 9.65.
Altman Z-Score | 9.65 |
Piotroski F-Score | n/a |